GENETIC POLYMORPHISM OF CYP2B6 AFFECTS THE PHARMACOKINETICS OF SIBUITRAMINE'S METABOLITE

被引：0
|
作者：
Cho, M. S. [1 ]
Jang, S. [1 ]
Lee, Y. [1 ]
Lim, L. [1 ]
Park, K. [1 ]
Chung, J. [1 ]
机构：
[1] Yonsei Univ, Coll Med, Seoul, South Korea
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2010年 / 87卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S53 / S53
页数：1
相关论文
共 50 条
  • [21] IMPACT OF UGT1A9 AND CYP2B6 POLYMORPHISM ON PHARMACOKINETICS OF PROPOFOL IN KOREAN PATIENTS.
    Kim, M.
    Jin, S.
    Noh, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S115 - S115
  • [22] Molecular simulation study of CYP2B6 polymorphism with and without psoralen
    Lu, Nan
    Meng, Fancui
    Xu, Weiren
    Tang, Lida
    Xu, Youjun
    MOLECULAR SIMULATION, 2018, 44 (17) : 1402 - 1410
  • [23] Pyrosequencing™-based screening for the genetic polymorphism CYP2B6 1459 C>T
    Doehring, Alexandra
    Loetsch, Joern
    PHARMACOGENOMICS, 2009, 10 (10) : 1577 - 1579
  • [24] The Effect of UGT 1A9, CYP2B6 and CYP2C9 Genes Polymorphism on Propofol Pharmacokinetics in Children
    Pavlovic, Dimitrije
    Budic, Ivana
    Stoimenov, Tatjana Jevtovic
    Stokanovic, Dragana
    Marjanovic, Vesna
    Stevic, Marija
    Slavkovic, Milan
    Simic, Dusica
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2020, 13 : 13 - 27
  • [25] Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver
    Lang, T
    Klein, K
    Fischer, J
    Nüssler, AK
    Neuhaus, P
    Hofmann, U
    Eichelbaum, M
    Schwab, M
    Zanger, UM
    PHARMACOGENETICS, 2001, 11 (05): : 399 - 415
  • [26] INFLUENCE OF THE CYP2B6*6 ALLELE ON THE PHARMACOKINETICS OF SIBUTRAMINE AND ITS ACTIVE METABOLITES
    Bae, S.
    Kim, W.
    Yeo, C.
    Cho, D.
    Shon, J.
    Shin, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S54 - S54
  • [27] CYP2B6*6 ALLELE ALTERS KETAMINE'S PHARMACOKINETICS IN CHRONIC PAIN PATIENTS AND METABOLISM IN VITRO
    Li, Yibai
    Coller, Janet K.
    Hutchinson, Mark R.
    Klein, Kathrin
    Zanger, Ulrich M.
    Currow, David
    Slon, Barry
    Jackson, Kate
    Somogyi, Andrew A.
    DRUG METABOLISM REVIEWS, 2014, 45 : 26 - 26
  • [28] THE EXTENT OF INHIBITION AND INDUCTION OF CYP2B6 BY EFAVRIENZ IS CYP2B6 GENOTYPE-DEPENDENT
    Duong, A.
    Gufford, B.
    Masters, A.
    Burgess, K.
    Lu, J.
    Metzger, I.
    Desta, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S36 - S36
  • [29] Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study
    Victorri-Vigneau, Caroline
    Verstuyft, Celine
    Bouquie, Regis
    Laforgue, Edouard-Jules
    Hardouin, Jean-Benoit
    Leboucher, Juliette
    Le Geay, Bertrand
    Dano, Corine
    Challet-Bouju, Gaelle
    Grall-Bronnec, Marie
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (07) : 1538 - 1543
  • [30] Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study
    Dobrinas, Maria
    Crettol, Severine
    Oneda, Beatrice
    Lahyani, Rachel
    Rotger, Margalida
    Choong, Eva
    Lubomirov, Rubin
    Csajka, Chantal
    Eap, Chin B.
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (02): : 84 - 93
12345